What is Antiviral Combination Therapies Market?
During the assessment period, the demand for antiviral combination therapies is expected to grow at a rapid pace. In order to innovate in combination therapy trials, medical institutes are increasing their efforts to partner with hospitals. Antiviral drugs combined with antibiotics have been found to have promising potential in reducing coronavirus symptoms in patients. Traditional Chinese medicine (TCM) combined with antiviral drugs for the treatment of chronic hepatitis B is one of the latest therapy avenues being investigated by healthcare companies (CHB). For red blood cells, the Chinese antiviral decoction YinQiSanHuang with entecavir is becoming more common.
The market study is being classified by Type (Branded and Generic) and major geographies with country level break-up.
Celltrion, Inc. (South Korea), GlaxoSmithKline plc (United Kingdom), Gilead Sciences, Inc. (United States), AbbVie, Inc. (United States), Bristol-Myers Squibb Company (United States), Janssen Global Services (United States), Cipla, Inc. (India), Mylan N.V. (United States), Merck & Co., Inc. (United States) and F. Hoffmann-La Roche Ltd. (Switzerland) are some of the key players profiled in the study.
The global Antiviral Combination Therapies market is highly competitive. To survive in the competitive market, key players adopted advanced healthcare technology for improved healthcare services. Furthermore, in order to retain market share and diversify its product portfolio, major players often adopt strategies such as mergers, acquisitions, and new product launches. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Antiviral Combination Therapies market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Antiviral Combination Therapies market by Type, Application and Region.
On the basis of geography, the market of Antiviral Combination Therapies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growth in Spending on Research & Development by Market Players for the Development of Effective Antiviral Combination Therapies for the Treatment of a Range of Viral Diseases
- Rising Ability of the Combination Therapy to Control the Antibiotic Resistance
- Stringent Regulatory Norms regarding Therapies
- Increase in Focus on Drug Repurposing and Vaccine Development for the Treatment of COVID-19
- Rising Number of Product Approvals for Combination Therapy
- High Cost of Antiviral Drug Treatment
In August 2020, Janssen Global Services entered into an agreement with the U.S. Government for the large-scale development and manufacturing of 100 million doses of Janssenís SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the U.S., following the approval of Emergency Use Authorization by the U.S. Food and Drug Administration (FDA), and In May 2020, Gilead received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Veklury (remdesivir), for the treatment of COVID-19 in Japanese patients
Key Target AudienceResearch Organisations, Government & Regulatory Bodies, Health Care Sector, Potential Investors and Downstream Vendors
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase